Norbrook Laboratories, Ltd. announced the FDA approval of Norfenicol (florfenicol) Injectable Solution, a treatment for Bovine Respiratory Disease associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somnus in beef and non-lactating dairy cattle.
Norfenicol is also indicated for the control of respiratory disease in cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni, as well as the treatment of bovine interdigital phlegmon (foot rot, acute interdigital necrobacillosis, infectious pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.
According to Chip Whitlow, marketing manager for Norbrook, Inc., Norfenicol has the same active ingredient as Nuflor (florfenicol) and will include two additional, innovative product features.
"The first is Norfenicol will have a shorter withdrawal period than Nuflor when administered Sub-Q (33 days vs. 38 days).
"In addition, Norfenicol will be the only injectable antibiotic for cattle sold in the US in an unbreakable plastic bottle. This eliminates the expense of product breakage when mishandled," Whitlow said.
New Norfenicol will soon be available from veterinarians in plastic 100 mL, 250 mL and 500 mL bottles.
For more information about new Norfenicol Injectable Solution, contact your veterinarian or local animal health products supplier or Norbrook, Inc. online.
See product labeling for full product information and directions, including adverse reactions.